Germany's Cannabis Import Boom Is Reshaping the EU Market

Photo by MART PRODUCTION via Pexels.

Start with the number that should stop anyone still calling this a niche market: 201,094 kilograms. That's how much medical cannabis Germany imported in 2025, nearly tripling the volume it brought in during 2024. Sales tied to that flower crossed one billion euros for the first time in the same year. This isn't a boutique pharmaceutical category anymore -- it's a commodity import business with the scale and messiness of one, complete with supply chain diversification, quota fights, and a legislature trying to figure out how it let things move this fast.

The momentum hasn't stopped. Q1 2026 imports hit 50,539 kg, up 34% year-over-year, though down roughly 15% from Q4 2025 -- the first real hint that the curve might be bending. Canada supplied 53% of that first-quarter total, still the anchor supplier even as Germany works to spread its sourcing around. Behind all of it sits the same mechanism that built the boom in the first place: telemedicine platforms that turned getting a medical cannabis prescription into something closer to ordering groceries than visiting a specialist. That looseness is now squarely in Berlin's crosshairs, with a Bundestag amendment fight that could reshape demand well before any quota renegotiation does. This piece walks through who's actually supplying Germany, why the country keeps running into its own import ceiling, and what happens to all of it depending on how a single piece of pending legislation shakes out.

How Germany Became Europe's Biggest Cannabis Buyer

Germany's medical cannabis imports nearly tripled from 67,000 kg in 2024 to over 201,000 kg in 2025, with quarterly figures for Q4 2025 (59,000 kg) and Q1 2026 (50,539 kg) suggesting continued strong demand.

Germany didn't become Europe's largest medical cannabis buyer through some grand five-year plan -- it backed into the role through a specific mix of decriminalization spillover and permissive prescribing. The headline figure is stark on its own: 201,094 kg imported in 2025 against roughly 70,000 kg the year before, a near-tripling in twelve months. Rolling twelve-month imports have since climbed past 218 tonnes, which tells you the growth didn't stop at the calendar year -- it kept compounding into 2026. Sales crossed one billion euros for the first time in 2025, a threshold that moves German medical cannabis out of the specialty-pharmacy conversation and into the same sentence as established generics categories.

The mechanism behind this is straightforward and well documented: telemedicine platforms built specifically around cannabis prescribing exploded in the wake of Germany's 2024 cannabis decriminalization, which normalized the plant culturally even as medical channels remained the only fully legal purchase route for flower. A patient consultation over video call, a same-day prescription, and delivery through a licensed pharmacy became a fast, low-friction loop -- fast enough that critics started calling some platforms rubber-stamp operations rather than genuine medical gatekeepers. Whatever you call it, the effect on volume is undeniable.

Q1 2026 data is the first real signal that the slope might be changing. Imports hit 50,539 kg, still up 34% from Q1 2025 -- genuine, substantial growth by any normal market's standard. But it's down about 15% from Q4 2025's total, and a single quarter isn't a trend. It could be seasonal restocking patterns, a temporary lull ahead of new supplier contracts, or the first real drag from tightening scrutiny on telehealth prescribing. Reading it as either roaring bull market or turning point is premature -- what's fair to say is that the multi-quarter streak of dramatic acceleration has, for now, paused.

Who's Actually Filling the Supply Gap

Photo by Pixabay via Pexels.

Canada remains the backbone of Germany's supply, and by a wide margin. In 2025 Canadian producers shipped 93,006 kg into Germany, a 46% share of total imports. That share actually grew in Q1 2026, reaching 53% on 26,753 kg -- meaning Germany's dependency on a single external supplier is, if anything, intensifying in the near term even as officials talk about diversification. Canada's advantage here is structural: a mature, GACP/EU-GMP-capable licensed producer base built originally for its own adult-use and medical markets, with spare capacity to export once domestic demand plateaued.

Portugal has become the key second pillar, and it's a meaningfully different kind of supplier because it's inside the EU. Portuguese shipments jumped from 17,230 kg in 2024 to 55,164 kg in 2025 -- more than tripling -- and Portugal held onto second place in Q1 2026 with 10,342 kg. That EU-based footprint matters for logistics: no third-country import certificates, shorter transit times, and cultivation operations (several backed by Canadian and multinational cannabis companies operating EU-GMP facilities in the Alentejo region) that were purpose-built to feed exactly this kind of demand.

Below those two, the supplier list is diversifying fast enough to look almost experimental. Australia's exports to Germany tripled to 4,190 kg. Malta went from a rounding error -- 161 kg in 2024 -- to 4,858 kg in 2025. Denmark grew to 9,319 kg, North Macedonia tripled its shipments to 8,190 kg, and the Czech Republic, Argentina, Colombia, and the UK each posted significant year-over-year gains. None of these individually threatens Canada's dominance. Collectively, though, they matter a great deal for resilience: a supply chain concentrated in one or two countries is one export policy change, currency shock, or crop failure away from a genuine shortage. A dozen meaningful suppliers, even small ones, gives German distributors room to absorb a disruption from any single source without the whole system seizing up. That's the quiet, unglamorous kind of market maturation that rarely makes headlines but tends to determine whether a market survives its first real supply shock.

The Quota Problem Nobody Outside Germany Noticed

Photo by Ylanite Koppens via Pexels.

Here's the part of this story that got almost no attention outside pharmaceutical trade circles, and it's arguably more structurally important than any single supplier's growth rate. Cannabis, even for medical use, is still a scheduled narcotic under the 1961 UN Single Convention on Narcotic Drugs. That treaty obligation means Germany -- like every signatory -- has to estimate its annual medical cannabis needs in advance and submit that estimate to the International Narcotics Control Board, which effectively sets a national import ceiling for the year. It's a bureaucratic artifact from an era when narcotic medicine meant morphine and codeine in tightly controlled hospital quantities, not a rapidly scaling consumer-facing pharmaceutical market.

Germany hit its 122-tonne ceiling in September 2025. BfArM, the federal drug regulator, was careful to clarify this wasn't a ban -- existing supply continued moving -- but new import applications started facing delays while the estimate got revised. That's a real cost even if it's not a headline-grabbing embargo: distributors and pharmacies dealing with unpredictable approval timelines, patients potentially facing gaps between prescription and fulfillment.

It took roughly two months for the ceiling to get raised, eventually landing at 192.5 tonnes. That's a substantial jump, but the math doesn't quite catch up: with rolling twelve-month imports already exceeding 218 tonnes by the time Q1 2026 data came in, Germany is almost certainly heading toward another squeeze against its own ceiling within the next reporting cycle. This isn't a policy failure so much as a mismatch between a treaty framework built for slow-moving pharmaceutical demand and a market that's been growing at double- and triple-digit percentage rates. Expect this same bottleneck-then-revision cycle to repeat annually until German demand growth slows enough for INCB estimates to actually get ahead of it -- or until Germany starts padding its estimates more aggressively, the way several other rapidly growing medical cannabis markets have learned to do after their first quota scare.

Berlin's Prescribing Crackdown Could Choke Its Own Growth Engine

Photo by Osviel Rodriguez Valdés via Pexels.

The regulatory story that could actually matter more than the quota fight is happening in the Bundestag, and it's aimed squarely at the mechanism that built this market: telemedicine prescribing. On 8 October 2025, Germany's Cabinet approved a MedCanG amendment that would require in-person prescribing for medical cannabis and ban mail-order dispensing outright -- effectively dismantling the video-call-to-delivery pipeline that drove the 2024-2025 volume tripling.

The bill had its first Bundestag reading on 18 December 2025 and moved to committee, which is where things currently sit. The Bundesrat, Germany's upper house representing the states, backed the tighter prescribing requirements in principle but rejected the mail-order dispensing penalties specifically -- a meaningful split that signals this isn't a rubber-stamp process. Members of the SPD have said publicly they won't approve the draft in its current form. As of late July 2026, the bill's status remains unresolved. This is worth stating plainly: this is genuinely contested legislation, not settled law, and anyone treating its passage as inevitable is getting ahead of the facts.

If it passes as originally drafted -- in-person prescribing required, mail-order banned -- the effect on demand growth would likely be sharp and fast. There's real precedent here: telehealth-driven prescribing booms in other therapeutic categories and other jurisdictions have historically cooled hard once in-person requirements got reinstated, because the entire growth engine depended on removing friction from the prescribing step, not on some newly discovered surge in underlying medical need. Reinsert that friction and volume growth tends to flatten quickly, sometimes within a couple of quarters.

The counter-case deserves equal weight, though. Given the Bundesrat's explicit rejection of the mail-order penalty and SPD resistance to the draft, a watered-down compromise -- tighter prescribing standards without an outright mail-order ban -- looks entirely plausible. That outcome would preserve most of the current growth trajectory while addressing the more legitimate criticism of the telehealth model, namely inconsistent clinical oversight rather than the delivery mechanism itself. Which version emerges from committee is the single most consequential open variable in this entire market right now.

The Rest of the EU Is Quietly Building Its Own Pipelines

Photo by Marco via Pexels.

Germany's boom tends to dominate the headlines, but treating it as an isolated bubble misses a broader pattern building across the EU -- one that looks a lot like how German toleration of cross-border medical cannabis access in the 2010s quietly preceded formal frameworks springing up elsewhere once neighboring regulators saw it wasn't causing chaos.

Spain took its first real regulatory step with RD 903/2025, moving from a patchwork of hospital-based compassionate use toward something resembling an actual functioning medical cannabis framework. It's early-stage compared to Germany, but it's a meaningful shift for a country that had largely sat on the sidelines of the EU's medical cannabis expansion.

The Czech Republic has moved further and faster. Starting in April 2025, prescriber access expanded to roughly 5,000 general practitioners -- a dramatic widening from a system that previously required specialist involvement -- paired with what's now the most generous reimbursement structure in the EU. That combination of broad prescriber access and real insurance coverage is arguably a more durable growth driver than Germany's telemedicine-fueled model, because it doesn't depend on a workaround that regulators might close.

Denmark made its pilot program permanent starting in 2025, after years of temporary extensions that left patients and cultivators alike uncertain whether the whole framework might simply expire. Permanence changes investment calculus -- it's the difference between a company treating Danish operations as a hedge and treating them as a real long-term production base, which likely explains why Danish exports to Germany grew to 9,319 kg in the same period.

Even Ukraine entered the picture, issuing its first medicine import license in June 2025 -- opening a new front for medical cannabis access despite wartime constraints that would reasonably be expected to push cannabis policy far down the priority list. That it happened at all says something about how normalized medical cannabis access has become as a policy conversation across the continent, war or no war.

None of these countries is close to Germany's volume. But together they read less like scattered experiments and more like an EU-wide normalization pattern building in parallel, each country contributing a different piece -- prescriber access, reimbursement, permanence, cross-border licensing -- of infrastructure that doesn't depend on any single country's political mood staying favorable.

Where the Volumes Go From Here

Photo by Terrance Barksdale via Pexels.

Run the Q1 2026 numbers forward at their current pace and you land around 200 tonnes for full-year 2026. Some analysts push that estimate higher, toward 250 tonnes, on the reasonable assumption that German demand shows back-half seasonality similar to 2025's pattern, where later quarters outpaced earlier ones. Both figures are extrapolations from a single data point, not certainties -- worth remembering given how much a quarter-over-quarter dip already showed up once this year.

One further-out figure is worth naming precisely because it needs the right framing: at least one industry analyst has floated 600 tonnes annually as Germany's eventual ceiling. That number should be read as a long-horizon speculative scenario, not a near-term forecast anyone should bank on. It would require the current growth trajectory to continue largely uninterrupted for several more years, the quota mechanism to keep getting revised upward reactively without political friction, and the MedCanG amendment fight to resolve in a way that preserves rather than restricts telehealth-driven demand. That's a lot of favorable assumptions stacked on top of each other.

The case for continued strong growth is real: Germany's quota keeps getting raised reactively rather than proactively rejected, meaning the ceiling has so far always bent to demand rather than the reverse. The supplier base is diversifying and de-risking in a way that reduces the odds of a supply-driven slowdown. And EU neighbors building complementary frameworks -- Czech reimbursement, Danish permanence, Spanish regulatory groundwork -- suggest a continent-wide demand base still expanding rather than saturating.

But the case for deceleration is at least as concrete. The MedCanG amendment fight is unresolved and specifically targets the prescribing mechanism that built this market. The Q1 2026 quarter-over-quarter dip, however preliminary, is the first real crack in an otherwise unbroken growth streak. And the treaty-based quota system is a structural drag by design -- it will keep forcing Germany to play catch-up with its own ceiling rather than getting ahead of demand, and each renegotiation cycle introduces friction and delay that dampens growth at the margins.

Readers should treat 600 tonnes as exactly what it is: one analyst's upper-bound scenario built on optimistic assumptions holding steady for years. The number that will actually determine 2026 and 2027 volumes is far more mundane and far more knowable in the near term -- what the Bundestag committee decides about mail-order dispensing.

Strip away the tonnage figures and the story underneath is fairly simple: Germany built a billion-euro import market on a specific, fragile combination of easy telemedicine prescribing and a quota ceiling that kept bending upward under pressure. Neither of those legs is guaranteed to hold, and critically, they can fail independently of each other. The quota could keep rising indefinitely while the Bundestag guts telehealth prescribing and demand growth stalls anyway. Or the amendment fight could resolve in cannabis's favor while Germany runs into an INCB estimate it's reluctant to revise a third time in two years. Either failure mode changes the trajectory on its own.

If there's one thing worth actually watching over the next several months, it's the Bundestag committee's resolution of the mail-order dispensing dispute. That single decision will do more to shape 2026 and 2027 import volumes than any supplier diversification story or quota renegotiation likely will, because it strikes directly at the demand mechanism rather than the supply mechanics around it.

But zoom out past Germany's raw tonnage, and the more durable story might be happening elsewhere entirely. Portugal's cultivation buildout, the Czech Republic's prescriber and reimbursement expansion, Denmark's permanent program, Spain's first real regulatory framework -- these are pieces of genuine infrastructure, not workarounds vulnerable to a single legislative session. Whatever Berlin decides about mail-order pharmacies, that infrastructure keeps existing, keeps generating supply and clinical capacity, and keeps building toward a version of the EU medical cannabis market that doesn't depend on any one country's political mood. Germany may end up remembered less as the market that hit 600 tonnes and more as the market whose regulatory stumbles gave its neighbors time to build something sturdier.